Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study

Published:2024-11 Issue:6 Volume:4 Page:100307
ISSN:2667-0267
Container-title:JID Innovations
language:en
Short-container-title:JID Innovations

Author:

Passeron Thierry^ORCID,Fontas Eric^ORCID,Boye Thierry^ORCID,Richard Marie-Aleth^ORCID,Delaporte Emmanuel^ORCID,Dereure Olivier^ORCID

Funder

Innate Pharma

Université Côte d'Azur

Publisher

Elsevier BV

Reference13 articles.

1. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management;Amber;Clin Rev Allergy Immunol,2018

2. Avdoralimab (anti-C5aR1 mAb) versus placebo in patients with severe COVID-19: results from a randomized controlled trial (FOR COVID elimination [FORCE]);Carvelli;Crit Care Med,2022

3. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid;Chen;J Clin Invest,2001

4. Complement activation in autoimmune bullous dermatoses: a comprehensive review;Edwards;Front Immunol,2019

5. The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid;Heimbach;J Biol Chem,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP